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Abstract: Sympathetic overactivity is associated with hyperhidrosis and cardiovascular diseases.
Endoscopic thoracic sympathectomy (ETS) is a treatment for hyperhidrosis. We aimed to compare the
risk for cardiovascular events between individuals with and without hyperhidrosis and investigate the
effects of ETS on cardiovascular outcomes. We conducted a nationwide population-based cohort study
using data acquired from the Korean Health Insurance Review and Assessment Service. Subjects newly
diagnosed with hyperhidrosis in 2010 were identified and divided into two groups according to
whether or not they underwent ETS. Propensity scores were calculated using a logistic regression
model to match hyperhidrosis patients with control subjects. Combined cardiovascular events were
defined as stroke and ischemic heart diseases. Subjects were followed up until the first cardiovascular
event or 31 December 2017. The risk for cardiovascular events with hyperhidrosis and ETS was
analyzed using Cox proportional hazards regression analysis. The risk for stroke was significantly
higher in the hyperhidrosis group than in the control group (hazard ratio (HR), 1.28; 95% confidence
interval (CI), 1.08–1.51); nonetheless, no significant difference in the risk for ischemic heart diseases
was observed between the hyperhidrosis group and the control group (HR, 1.17; 95% CI, 0.99–1.31).
Hyperhidrosis patients who did not undergo ETS were at significantly higher risk for cardiovascular
events than the control group (HR, 1.28; 95% CI, 1.13–1.45). However, no significant difference in the
risk for cardiovascular events was observed between hyperhidrosis patients who underwent ETS and
the control group. Hyperhidrosis increases the risk for cardiovascular events. ETS could reduce this
risk and needs to be considered for high-risk patients with cardiovascular diseases.
Keywords: cardiovascular diseases; endoscopic thoracic sympathectomy; hyperhidrosis;
sympathetic overactivity
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1. Introduction
Hyperhidrosis is a pathologic condition characterized by excessive sweating beyond physiological
needs. Hyperhidrosis can lead to substantial impairment in the quality of life [1] and has an estimated
prevalence rate of approximately 2.8% (7.8 million individuals) in the United States [2]. The pathogenesis
of this condition remains incompletely understood. Nonetheless, primary hyperhidrosis, defined as
inordinate sweating with an unknown identifiable cause, has been suggested to be due to sympathetic
nervous system overactivity [3–5].
Accumulating evidence has indicated the association between sympathetic nervous system
overactivity and cardiovascular disease development and progression [6–9]. Sympathetic overactivity
plays a key role in the induction and maintenance of hypertension [6,10,11]. Among congestive heart
failure patients, individuals with sympathetic overactivity have been reported to have higher mortality
rates than those without it [12,13].
Endoscopic thoracic sympathectomy (ETS) is a surgical procedure involving the transection and
clamping of the upper thoracic chain of the sympathetic nerve trunk and is considered one of the
treatment methods for primary hyperhidrosis to reduce sympathetic overactivity [14,15]. After ETS,
hyperhidrosis patients have been observed to exhibit a reduction in noradrenaline and adrenaline
levels, heart rate, blood pressure, cardiac index, and myocardial oxygen demand [16]. A recent
epidemiological study has reported that hyperhidrosis patients who underwent ETS had a reduced
risk of cardiovascular events [17]. However, few studies have investigated the relationship between
cardiovascular disease and hyperhidrosis and evaluated the effect of ETS on cardiovascular outcomes
in hyperhidrosis patients. The present study aimed to compare the incidence and risk of cardiovascular
events between individuals with and without hyperhidrosis and to investigate the effects of ETS on
cardiovascular outcomes in the Korean population. We conducted a large retrospective cohort study
using a claims database that includes the entire population of South Korea.
2. Materials and Methods
2.1. Data Sources
Data were acquired from the Korean Health Insurance Review and Assessment (HIRA) Service.
Approximately 97% of the Korean population is covered by the Korean National Health Insurance,
whereas the remaining approximately 3% who cannot afford national insurance are covered by
the Medical Aid Program [18]. The HIRA, a central office in the Korean Ministry of Health
and Welfare, was established to review claims data and assess the medical care quality in South
Korea. Furthermore, the HIRA is responsible for maintaining an electronic database that provides
information on inpatient and outpatient visits in all Korean healthcare institutions, healthcare billing,
and reimbursement claims submitted to the Korean National Health Insurance and Medical Aid
Program [19]. The HIRA database contains enormous epidemiological information on demographics,
diagnoses, and medical services (procedures and operations), and the diagnosis codes are standardized
in accordance with the 7th version of the Korean Classification of Disease, which is a modified version
of the 10th edition of the International Classification of Diseases.
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki,
as reflected in a priori approval by the institutional review board of Yonsei University Gangnam
Severance Hospital (institutional review board number 3-2018-0195). The requirement for the
acquisition of informed consent from patients was waived because the present study was a retrospective
observational study with an anonymized dataset.
2.2. Study Population and Design
In this retrospective cohort study, de-identified data on health claims from 1 January 2007 to
31 December 2017 were extracted from the HIRA database. We reviewed the data recorded in the HIRA
database and identified patients with primary hyperhidrosis (diagnosis code: R61) who underwent
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ETS (procedure codes: S4832 and LA361). Combined cardiovascular events were defined as stroke
(I60–I64) and ischemic heart diseases (I21–I25). Stroke included hemorrhagic stroke (I60–I62), ischemic
stroke (I63), and unspecified stroke (I64), whereas ischemic heart diseases included acute myocardial
infarction (I21–I23) and ischemic heart disease (I24–I25).
Following the exclusion of hyperhidrosis patients with cardiovascular events (stroke and ischemic
heart diseases) prior to 2010, individuals were divided into two groups according to whether or
not they were diagnosed with hyperhidrosis in 2010. As the incidence of hyperhidrosis was lower
with advanced age, individuals aged 18–65 years were included in the analysis [20]. In order to
match hyperhidrosis patients with control subjects, propensity scores were calculated using a logistic
regression model based on the following variables: Age, sex, and comorbidities (diabetes mellitus
[E10–E14], hypertension [I10–I15], atrial fibrillation [I48], dyslipidemia [E78], congestive heart failure
[I50], mood disorder [F30–F39], anxiety disorder [F40–F41], renal disease [N17–N19], and malignant
neoplasm [C00–D48]). Further analysis was performed by dividing hyperhidrosis patients into those
who underwent ETS and those who did not. Subjects were followed up until the first cardiovascular
event or 31 December 2017. A flowchart of the study design is presented in Figure 1.
Figure 1. Flowchart of subject selection from the Health Insurance Review and Assessment Service
database of Korea.
2.3. Statistical Analyses
Descriptive statistics were calculated to analyze the control subjects and hyperhidrosis patients
who underwent ETS and those who did not. The characteristics of study subjects were compared using
t-test and one-way analysis of variance for continuous variables and chi-squared test for categorical
variables. Mean and proportion differences between groups were determined using post-hoc analysis
of variance and chi-squared test with Bonferroni corrections. Kaplan–Meier curves were constructed,
and comparisons were performed using the log-rank test. We calculated the hazard ratio (HR) and 95%
confidence interval (95% CI) with Cox proportional hazards regression analysis. Statistical significance
was set at p-value < 0.05 (overall), and all statistical analyses were performed using SAS statistical
software (version 9.4.2; SAS Institute Inc., Cary, NC, USA).
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3. Results
With a median follow-up time of 7.7 years, 33,746 patients in total were diagnosed with
hyperhidrosis in 2010, whereas 45,125,621 individuals were not. Following the exclusion of
hyperhidrosis patients with cardiovascular events (stroke and ischemic heart diseases) prior to
2010, 19,475 patients were deemed to have hyperhidrosis, whereas 45,432,866 individuals were not
(controls). Among these individuals, those aged 18–65 years were included in the analysis, resulting in
a total of 18,613 hyperhidrosis patients and 29,267,138 controls. After propensity score matching by age,
sex, and comorbidities, the study cohort comprised 18,613 hyperhidrosis patients and 18,613 controls
(Figure 1).
Table 1 presents the baseline characteristics of the study subjects. No significant differences in
mean age, sex, and comorbidities were observed between the control and the hyperhidrosis groups.
Among 18,613 hyperhidrosis patients, 2404 patients underwent ETS, whereas 16,209 patients did not.
During the follow-up period, 462 and 571 cardiovascular events were identified in the control and
hyperhidrosis groups, respectively (Figure 1).
Table 1. Baseline characteristics of the study subjects according to the presence or absence of
hyperhidrosis and ETS status.
Control Hyperhidrosis p-Value Control
Hyperhidrosis
p-Value Post Hoc
Without ETS With ETS
N 18,613 18,613 18,613 16,209 2404
Age (years) 32.8 ± 12.2 32.8 ± 12.2 0.961 32.8 ± 12.2 33.4 ± 12.4 28.8 ± 9.9 <0.001 a, b, c
Sex 0.909 0.041 b, c
Female 9123 (49.0%) 9134 (49.1%) 9123 (49.0%) 8012 (49.4%) 1122(46.7%)
Male 9490 (51.0%) 9479 (50.9%) 9490 (51.0%) 8197 (50.6%) 1282(53.3%)
Comorbidity
Diabetes mellitus 640 (3.4%) 633 (3.4%) 0.842 640 (3.4%) 609 (3.8%) 24 (1.0%) <0.001 b, c
Hypertension 1301 (7.0%) 1292 (7.0%) 0.855 1301 (7.0%) 1204 (7.4%) 88 (3.7%) <0.001 b, c
Atrial fibrillation 47 (0.3%) 37 (0.2%) 0.275 47 (0.3%) 34 (0.2%) 3 (0.1%) 0.394 —
Dyslipidemia 1185 (6.4%) 1202 (6.5%) 0.719 1185 (6.4%) 1096 (6.8%) 106 (4.4%) <0.001 b, c
Congestive heart failure 22 (0.1%) 22 (0.1%) >0.999 22 (0.1%) 21 (0.1%) 1 (0.1%) 0.504 —
Mood disorder 862 (4.6%) 853 (4.6%) 0.824 862 (4.6%) 785 (4.8%) 68 (2.8%) <0.001 b, c
Anxiety disorder 809 (4.4%) 809 (4.4%) >0.999 809 (4.4%) 733 (4.5%) 76 (3.2%) 0.009 b, c
Renal disease 46 (0.2%) 31 (0.2%) 0.087 46 (0.2%) 30 (0.2%) 1 (0.1%) 0.081 —
Malignant neoplasm 243 (1.3%) 225 (1.2%) 0.402 243 (1.3%) 210 (1.3%) 15 (0.6%) 0.016 b, c
Data are presented as mean ± standard deviation or N (percentage); p-values were calculated using t-test or one-way
analysis of variance for continuous variables and chi-squared test for categorical variables. Post-hoc analysis of
variance for the mean difference between groups: a, control vs. hyperhidrosis patients who did not undergo ETS;
b, control vs. hyperhidrosis patients who underwent ETS; c, hyperhidrosis patients who did not undergo ETS vs.
hyperhidrosis patients who underwent ETS. ETS: Endoscopic thoracic sympathectomy.
The cumulative incidence of cardiovascular events including stroke and ischemic heart diseases
was significantly higher in the hyperhidrosis group than in the control group (log-rank p = 0.002;
Figure 2). The results of univariate and multivariate Cox regression analyses for the risk of stroke,
ischemic heart disease, and combined cardiovascular events are shown in Table 2. The hyperhidrosis
group had a significantly higher risk for combined cardiovascular events than the control group (HR,
1.24; 95% CI, 1.10–1.41) after adjustment for age, sex, and comorbidities.
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Figure 2. Kaplan–Meier curves with cumulative incidence of cardiovascular events stratified by the
presence or absence of hyperhidrosis using log-rank test.
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Table 2. Hazard ratio for cardiovascular events according to the presence or absence of hyperhidrosis
determined through Cox regression analysis.
Control Hyperhidrosis
Stroke
Crude HR (95% CI) 1 (reference) 1.24 (1.05–1.47)
Adjusted HR 1 (95% CI) 1 (reference) 1.28 (1.08–1.51)
Ischemic heart diseases
Crude HR (95% CI) 1 (reference) 1.16 (0.98–1.38)
Adjusted HR 1 (95% CI) 1 (reference) 1.17 (0.99–1.39)
Combined cardiovascular events
Crude HR (95% CI) 1 (reference) 1.22 (1.08–1.37)
Adjusted HR 1 (95% CI) 1 (reference) 1.24 (1.10–1.41)
1 Adjusted for age, sex, and comorbidities (diabetes mellitus, hypertension, atrial fibrillation, dyslipidemia,
congestive heart failure, mood disorder, anxiety disorder, renal disease, malignant neoplasm). HR: Hazard ratio; CI:
Confidence interval.
However, no significant difference in the cumulative incidence of cardiovascular events including
stroke and ischemic heart diseases was observed between the control group and hyperhidrosis patients
who underwent ETS. Furthermore, the cumulative incidence of combined cardiovascular events was
higher in hyperhidrosis patients who did not undergo ETS than in the control group (log-rank p <
0.001; Figure 3). Table 3 presents the HR for cardiovascular events according to ETS status determined
through Cox regression analysis. Hyperhidrosis patients who did not undergo ETS had a significantly
higher risk for combined cardiovascular events than control patients (HR, 1.28; 95% CI, 1.13–1.45) after
adjustment for age, sex, comorbidities. However, the risk of combined cardiovascular events did not
significantly differ between hyperhidrosis patients who underwent ETS and the control group (HR,
0.89; 95% CI, 0.63–1.26).
Table 3. Hazard ratio for cardiovascular events according to ETS status determined through Cox
regression analysis.
Control
Hyperhidrosis
Without ETS With ETS
Stroke
Crude HR (95% CI) 1 (reference) 1.36 (1.15–1.61) 0.44 (0.26–0.75)
Adjusted HR 1 (95% CI) 1 (reference) 1.32 (1.12–1.57) 0.72 (0.42–1.24)
Ischemic heart diseases
Crude HR (95% CI) 1 (reference) 1.24 (1.05–1.48) 0.62 (0.39–0.98)
Adjusted HR 1 (95% CI) 1 (reference) 1.19 (1.01–1.41) 0.97 (0.61–1.53)
Combined cardiovascular events
Crude HR (95% CI) 1 (reference) 1.31 (1.16–1.49) 0.56 (0.40–0.79)
Adjusted HR 1 (95% CI) 1 (reference) 1.28 (1.13–1.45) 0.89 (0.63–1.26)
1 Adjusted for age, sex, and comorbidities (diabetes mellitus, hypertension, atrial fibrillation, dyslipidemia,
congestive heart failure, mood disorder, anxiety disorder, renal disease, malignant neoplasm).
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Figure 3. Kaplan–Meier curves with cumulative incidence of cardiovascular events stratified by the
presence or absence of hyperhidrosis and Endoscopic thoracic sympathectomy (ETS) status using
log-rank test.
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4. Discussion
Hyperhidrosis is characterized by excessive sweating beyond the thermoregulatory requirements,
and several patients suffer from this condition, resulting in a negative impact on their quality of life
owing to emotional, physical, or social discomfort. Although the etiology of primary hyperhidrosis
remains obscure, an increase in sympathetic activity and autonomic imbalance in hyperhidrosis patients
have recently been reported [21]. In addition, sympathectomy for hyperhidrosis patients has been
shown to confer cardiovascular benefits [17,22,23]. Nakamura et al. reported that ETS decreased
the myocardial oxygen demand via a reduction in heart rate and arterial pressure [16]. Cruz et al.
demonstrated that ETS increased cardiac autonomic activity [22]. Recently, Cheng et al. have shown
that ETS reduced the risk of cardiovascular events in hyperhidrosis patients [17], which is consistent
with the results of our study. However, there exist few previous studies to allow for a comparison of
the incidence and risk of cardiovascular events between individuals with and without hyperhidrosis;
thus, it remains unknown whether hyperhidrosis increases the risk of cardiovascular diseases. To the
best of our knowledge, our study is the first to compare cardiovascular outcomes between individuals
with and without hyperhidrosis using nationwide population-based cohort data. We determined
that hyperhidrosis patients had a significantly higher risk for cardiovascular events than individuals
without hyperhidrosis. However, when we divided cardiovascular events into stroke and ischemic
heart diseases, the risk for ischemic heart diseases in the hyperhidrosis group did not significantly
differ from that in the control group. As the hyperhidrosis group included both hyperhidrosis patients
who did and those who did not undergo ETS, it is assumed that the overall effect of hyperhidrosis
on ischemic heart diseases might have been weakened. In our study, hyperhidrosis patients who did
not undergo ETS had a significantly higher risk for combined cardiovascular events than the control
subjects. On the contrary, hyperhidrosis patients who underwent ETS and control subjects showed
comparable cardiovascular outcomes.
The exact underlying mechanisms for the relationship between hyperhidrosis and cardiovascular
events remain uncertain; nevertheless, chronic sympathetic overactivity plays a key pathophysiological
role in both conditions. Thermoregulation through sweat production is controlled by cerebral
cortical structures, the preoptic region of the anterior hypothalamus [24], and the sympathetic
nervous system [25]. Because the sweat glands are innervated by sympathetic cholinergic nerve
fibers [4], the activation of the sympathetic nervous system could stimulate sweat secretion,
and the sweat glands could respond to catecholamines in emotionally induced sweating [26,27].
Furthermore, sympathetic overactivity could increase the catecholamine-mediated modulation of heart
rate, vasomotor tone [11,28], and platelet aggregability [29] and contribute to the activation of the
renin–angiotensin–aldosterone system, subsequently stimulating myocardial contractility, constricting
peripheral arteries, and promoting heart failure and atherosclerosis [11,30–32].
Noninvasive strategies such as behavioral changes and antiperspirant use are considered
first-choice treatments for hyperhidrosis; however, surgery can be considered for severe hyperhidrosis
patients who fail to respond to conservative treatments. ETS has been regarded as the intervention
of choice for primary hyperhidrosis to reduce sympathetic overactivity owing to its high
success rate, low morbidity, relative ease of accessibility, and short recovery time required [33].
Hyperhidrosis patients who undergo ETS occasionally have the potential risk of compensatory
sweating, the most common side effect. However, growing evidence has shown that ETS as a treatment
for hyperhidrosis has additional cardiovascular protective effects. Recent studies have reported a
decrease in heart rate and sympathetic activity and an increase in vagal and cardiac autonomic activities
among patients who underwent ETS [22,34]. Jeng et al. reported increased carotid artery flow volume,
increased middle cerebral artery flow velocity, and reduced blood pressure in hyperhidrosis patients
after ETS [23]. In keeping with these studies, our study showed that hyperhidrosis patients who
did not undergo ETS had a higher risk for combined cardiovascular events including stroke and
ischemic heart diseases than the control group. However, no significant difference in the risk of
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combined cardiovascular events including stroke and ischemic heart diseases was observed between
the hyperhidrosis patients who underwent ETS and the control group.
Our study has several limitations. First, the HIRA database provides limited information about
patients (age, sex, diagnostic date, diagnostic codes, and procedure codes) and does not include the
entire medical records. Therefore, we could not exactly estimate the cardiovascular risks and events
in hyperhidrosis patients, and cardiovascular event prevalence and incidence rates could have been
possibly overestimated. Second, the HIRA database does not contain detailed data on hyperhidrosis
characteristics such as the location, severity, duration, and presence of compensatory hyperhidrosis;
laboratory and radiologic findings; socioeconomic status (educational level and income); and other
clinical considerations that may potentially affect cardiovascular events (e.g., alcohol consumption,
smoking status, body mass index, physical activity, family history). Third, we did not match ETS
patients versus non-ETS patients by propensity score. However, to minimize this limitation, we adjusted
significant covariates, including age, sex, and variable comorbidities that might potentially affect
cardiovascular events (diabetes mellitus, hypertension, atrial fibrillation, dyslipidemia, congestive
heart failure, mood disorder, anxiety disorder, renal disease, malignant neoplasm) in the Cox regression
analysis. Fourth, we did not divide stroke outcomes into ischemic and hemorrhagic stroke. A previous
study reported that although hyperhidrosis patients who underwent ETS showed a reduced risk of
ischemic stroke, ETS was not associated with a reduction in hemorrhagic stroke [35]. Further studies
are warranted to establish the effects of hyperhidrosis according to stroke types (ischemic and
hemorrhagic stroke). Lastly, because our study is not a randomized controlled trial, it is possible
that residual confounding factors remain, and we could not confirm the causal relationship between
hyperhidrosis and cardiovascular diseases. Despite these potential limitations, we performed a large
population-based cohort study with a relatively long duration, covering >99% of the South Korean
population. In addition, to minimize confounding factors, age, sex, and well-known cardiovascular
comorbidities were matched by propensity scores and adjusted for in the Cox regression analysis.
5. Conclusions
Hyperhidrosis patients showed a significantly higher risk for cardiovascular events than
individuals without hyperhidrosis, and ETS could reduce the risk of cardiovascular events in
hyperhidrosis patients. Physicians should pay attention to potential cardiovascular risks when treating
hyperhidrosis patients, and ETS needs to be considered for high-risk patients with cardiovascular
diseases despite the presence of compensatory hyperhidrosis and potential complications of ETS.
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